HANDA PHARMACEUTICALS, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 137 TWD | -2.49% |
|
+10.04% | -25.34% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 2.55B 79.11M 6.6B | Sales 2025 * | - | Capitalization | 19.33B 600M 50B |
|---|---|---|---|---|---|
| Net income 2024 * | 2.08B 64.53M 5.38B | Net income 2025 * | - | EV / Sales 2024 * | 6.32 x |
| Net cash position 2024 * | 3.22B 99.87M 8.33B | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
8.57
x | P/E ratio 2025 * |
-
| Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.49% | ||
| 1 week | +10.04% | ||
| Current month | +10.04% | ||
| 1 month | -14.11% | ||
| 3 months | -23.68% | ||
| 6 months | -3.52% | ||
| Current year | -25.34% |
1 week
132.00
145.50
1 month
105.00158.50
Current year
105.00196.00
1 year
105.00206.00
3 years
23.50221.00
5 years
15.45221.00
10 years
15.45221.00
| Managers | Title | Age | Since |
|---|---|---|---|
Fang Yue Liu
CEO | Chief Executive Officer | - | 01/05/01 |
Hsin Yue Chen
DFI | Director of Finance/CFO | - | - |
Mei Fang Chang
BRD | Director/Board Member | - | 08/16/08 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chun Liang Chen
BRD | Director/Board Member | - | 28/19/28 |
Kuei Ching Wang
BRD | Director/Board Member | - | 28/17/28 |
Wei Li Lin
BRD | Director/Board Member | - | 28/17/28 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/24/14 | 137 | -2.49% | 954,502 |
| 13/24/13 | 140.5 | +1.08% | 1,273,946 |
| 10/24/10 | 139 | +2.58% | 1,007,281 |
| 09/24/09 | 135.5 | +0.74% | 1,055,593 |
| 08/24/08 | 134.5 | +8.03% | 1,382,502 |
End-of-day quote Taipei Exchange, May 14, 2024
More quotes
Handa Pharmaceuticals Inc is a Taiwan-based pharmaceutical company focused on the development of niche drug. The Company integrates its own pharmaceutical development platform with patent analysis, medicine and pharmaceuticals regulatory, and market planning to focus on the development of high barrier and patentable niche products, including 505(b)2 new drug development and high barrier/patentable generics development. Its products include marketed products, such as Quetiapine XR Tablets for treatment of sleep disorder diseases, Lamotrigine XR Tablets for treatment of anti-epileptic diseases and Dexlansoprazole DR Capsules for treatment of erosive reflux esophagitis and non-erosive gastroesophageal reflux diseases. The Company's products are mainly sold to the United States, Canada and India.
Sector
Pharmaceuticals
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
137
TWD
Average target price
200
TWD
Spread / Average Target
+45.99%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -25.34% | 611M | |
| +22.69% | 43.81B | |
| +24.96% | 23.01B | |
| +18.00% | 15.27B | |
| +8.91% | 13.68B | |
| +42.72% | 11.96B | |
| -7.47% | 6.98B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +12.22% | 5.59B |
- Stock Market
- Equities
- 6620 Stock
